文献速递脑血管病

不同梗死模式短暂性脑缺血发作和小卒中患者的双联抗血小板治疗:CHANCE随机临床试验亚组分析

Dual Antiplatelet Therapy in Transient Ischemic Attack and Minor Stroke With Different Infarction Patterns: Subgroup Analysis of the CHANCE Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2018-01-01

该研究为CHANCE随机临床试验的预设影像学亚组分析,纳入1089例非心源性栓塞性TIA或小卒中患者,按弥散加权成像分为多发急性梗死、单发急性梗死和无急性梗死。多发急性梗死患者复发卒中风险最高,且从氯吡格雷联合阿司匹林治疗中获益最明显,未增加中重度出血风险。

要点

  • 多发急性梗死患者3个月复发卒中风险显著高于无急性梗死患者(HR 5.8)。
  • 多发急性梗死患者接受氯吡格雷联合阿司匹林较安慰剂加阿司匹林降低卒中复发风险(HR 0.5)。
  • 氯吡格雷联合阿司匹林未增加中重度出血风险。

核心结论

  • 梗死模式可有效分层非心源性栓塞性TIA或小卒中后3个月内复发卒中风险。
  • 多发急性梗死患者从双联抗血小板治疗中获益最明显,且未增加中重度出血风险。
  • 即使接受双联抗血小板治疗,多发急性梗死患者的卒中复发风险仍与单发急性梗死患者相当。

研究设计与样本

  • CHANCE随机临床试验的预设影像学亚组分析,纳入45个中心的1342例非心源性栓塞性TIA或小卒中患者,最终分析纳入1089例具备所需磁共振成像序列的患者。
  • 患者按弥散加权成像分为多发急性梗死、单发急性梗死和无急性梗死三组。
  • 主要疗效终点为3个月卒中复发,次要疗效终点为3个月新发临床血管事件,安全性终点为3个月中重度出血风险。

主要发现

  • 1089例患者平均(SD)年龄63.1(10.7)岁,男性731例(65%)。
  • 校正潜在混杂因素后,3个月随访时多发急性梗死患者复发卒中风险高于无急性梗死患者(HR 5.8;95%CI 2.2-15.1;P<.001),单发急性梗死患者亦高于无急性梗死患者(HR 3.9;95%CI 1.5-10.5;P=.007)。
  • 多发急性梗死组中,氯吡格雷联合阿司匹林组卒中复发15例(10.1%),安慰剂加阿司匹林组25例(18.8%)(HR 0.5;95%CI 0.3-0.96;P=.04)。
  • 单发急性梗死组中,氯吡格雷联合阿司匹林组卒中复发24例(8.9%),安慰剂加阿司匹林组24例(8.5%)(HR 1.1;95%CI 0.6-2.0;P=.71)。
  • 无急性梗死组中,氯吡格雷联合阿司匹林组卒中复发3例(2.6%),安慰剂加阿司匹林组2例(1.4%)(HR 1.7;95%CI 0.3-11.1;P=.56);治疗与梗死模式交互作用P=.04。

关键数值与推荐

  • 梗死模式分组标准:根据弥散加权成像分为多发急性梗死、单发急性梗死和无急性梗死。
  • 主要疗效终点为3个月卒中复发,次要疗效终点为3个月新发临床血管事件,安全性终点为3个月中重度出血风险。

临床怎么用

  • 梗死模式可用于分层非心源性栓塞性TIA或小卒中后3个月内复发卒中风险。
  • 多发急性梗死患者可从氯吡格雷联合阿司匹林双联抗血小板治疗中获益,且未增加中重度出血风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Infarction patterns may serve as important imaging markers to assess the probability of stroke recurrence in transient ischemic attack (TIA) and minor stroke. However, it is unclear whether patients with different infarction patterns benefit differently from dual antiplatelet therapy. OBJECTIVES: To investigate whether infarction patterns can stratify the risk of recurrent stroke and whether the efficacy and safety of clopidogrel plus aspirin vs aspirin alone are consistent in different infarction patterns after TIA or minor stroke. DESIGN, SETTING, AND PARTICIPANTS: In this prespecified imaging substudy of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) randomized clinical trial, a total of 1342 patients with noncardioembolic TIA or minor stroke at 45 sites of CHANCE from October 1, 2009, to July 30, 2012, were included in this substudy. The final analysis was conducted on July 30, 2016, and included 1089 patients with required magnetic resonance imaging sequences. Infarction patterns were grouped into multiple acute infarctions (MAIs), single acute infarction (SAI), and no acute infarction (NAI) according to diffusion-weighted imaging. MAIN OUTCOMES AND MEASURES: Primary and secondary efficacy outcomes were stroke recurrence and new clinical vascular event after 3 months, respectively. The safety outcome was moderate to severe bleeding risk after 3 months. RESULTS: Among 1089 patients, the mean (SD) age was 63.1 (10.7) years and 731 patients (65%) were men. Patients with MAIs (hazard ratio [HR], 5.8; 95% CI, 2.2-15.1; P < .001) and SAI (HR, 3.9; 95% CI, 1.5-10.5; P = .007) had higher risk of recurrent stroke than those with NAI after adjustment for potential confounders at 3-month follow-up. Stroke recurrence occurred in 15 (10.1%) and 25 (18.8%) of patients with MAIs administered clopidogrel plus aspirin and placebo plus aspirin, respectively (HR, 0.5; 95% CI, 0.3-0.96; P = .04), 24 (8.9%) and 24 (8.5%) of patients with SAI administered clopidogrel plus aspirin and placebo plus aspirin, respectively (HR, 1.1; 95% CI, 0.6-2.0; P = .71), and 3 (2.6%) and 2 (1.4%) of patients with NAI administered clopidogrel plus aspirin and placebo plus aspirin, respectively (HR, 1.7; 95% CI, 0.3-11.1; P = .56), with P = .04 for treatment × infarction pattern interaction effect. Clopidogrel plus aspirin did not increase moderate to severe bleeding risk. CONCLUSIONS AND RELEVANCE: Infarction patterns can efficiently stratify the risk of recurrent stroke within 3 months of noncardioembolic TIA or minor ischemic stroke. Patients with MAIs received the most pronounced clinical benefit from dual antiplatelet therapy without increasing the risk of moderate to severe bleeding. However, even if after dual antiplatelet treatment, patients with MAIs still had a risk of stroke recurrence as high as those with SAI. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00979589.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Jing J, Meng X, Zhao X, et al. Dual Antiplatelet Therapy in Transient Ischemic Attack and Minor Stroke With Different Infarction Patterns: Subgroup Analysis of the CHANCE Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 29582084. doi:10.1001/jamaneurol.2018.0247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。